Quoin net loss widens 45.32% to $5.4 million in Q2 FY26
QNRX•FDA updates on QRX003 programs
The FDA conditionally cleared QYLEKI as QRX003’s proposed brand name for Netherton syndrome. Quoin also cited a positive pediatric compassionate-use update.
The FDA cleared an IND for QRX003 in Peeling Skin Syndrome, enabling a Phase 2/3 study planned to start in the second half of 2026.
Q2 net loss widens on higher R&D spending
Quoin Pharmaceuticals posted a Q2 net loss of $5.37 million, widening from $3.7 million a year earlier.
- R&D expense climbed to $3.63 million from $2.05 million.
- G&A expense rose to $1.85 million from $1.74 million.
- Cash, cash equivalents, and marketable securities totaled $10.8 million at June 30; management expects funding into 2027.
